P2X7 receptor-dependent microglia-astrocyte coupling in Alzheimer's disease: from eATP sensing to synaptic and proteostatic failure
Authors:
Open Access
- 17 August 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 18, 1915244
Abstract
Alzheimer's disease (AD) is characterized not only by amyloid-β and tau pathology but also by progressive failure of multicellular homeostasis. The P2X7 receptor (P2X7R), a low-affinity ATP-gated ion channel preferentially activated in extracellular ATP-rich pathological microenvironments, is well positioned to translate local tissue stress into sustained glial dysfunction. Although P2X7R has traditionally been studied as a microglial inflammasome-associated receptor, its broader significance may lie in coupling microglial activation to astrocytic loss of homeostatic support. In this review, we propose an integrative model in which P2X7R functions as a high-threshold inter-glial transducer through five interconnected axes: extracellular ATP amplification, cytokine relay, extracellular vesicle exchange, convergent synaptic modulation and circuit destabilization, and a coordinated clearance-to-retention switch. Microglial P2X7R activation promotes cytokine and reactive oxygen species production, vesicle and mitochondrial release, inflammatory reprogramming, and impaired phagocytic and lysosomal competence. Astrocytic P2X7R may reinforce this environment through feed-forward ATP release, altered gliotransmission, reactive transformation, extracellular vesicle shedding, and disrupted autophagic and lysosomal processing. We further situate this reciprocal loop within the amyloid plaque niche, where dystrophic neurites, stressed synapses, and reactive glia may create a spatially restricted P2X7R-sensitive ATP microdomain. The resulting cross-glial amplification is proposed to connect neuroinflammation with synaptic destabilization and defective proteostasis. This framework also suggests that brain-penetrant and pharmacologically selective P2X7R antagonists could complement protein-targeted therapies, particularly when guided by functional biomarkers of receptor activity. However, the proposed coupling architecture remains an integrative and testable hypothesis because much of the supporting evidence derives from non-AD models, in vitro studies, or correlative human tissue analyses. Cell-type-specific, temporally resolved studies are therefore required to establish whether P2X7R-dependent microglia–astrocyte coupling causally drives AD progression.Keywords
This publication has 143 references indexed in Scilit:
- P2RX7 plays a critical role in extracellular vesicle‐mediated secretion of pathogenic molecules from microglia and astrocytesJournal of Extracellular Biology, 2024
- Donanemab in Early Symptomatic Alzheimer DiseaseJAMA, 2023
- Mechanisms underlying sensitization of P2X7 receptors in astrocytes for induction of ischemic toleranceGlia, 2021
- Reactive astrocytes as treatment targets in Alzheimer's disease—Systematic review of studies using the APPswePS1dE9 mouse modelGlia, 2021
- The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseasesMedicinal Research Reviews, 2020
- The P2X7 Receptor2017
- Hypoxia‐independent mechanisms of HIF‐1α expression in astrocytes after ischemic preconditioningGlia, 2017
- P2X7R‐mediated Ca2+‐independent d‐serine release via pannexin‐1 of the P2X7R‐pannexin‐1 complex in astrocytesGlia, 2015
- Astrocyte–neuron interaction in the substantia gelatinosa of the spinal cord dorsal horn via P2X7 receptor‐mediated release of glutamate and reactive oxygen speciesGlia, 2014
- Mechanosensitive release of adenosine 5′‐triphosphate through pannexin channels and mechanosensitive upregulation of pannexin channels in optic nerve head astrocytes: A mechanism for purinergic involvement in chronic strainGlia, 2014